NYSE:ALBAlbemarle Stock Price, Forecast & News

Albemarle's stock was trading at $70.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALB stock has increased by 24.5% and is now trading at $87.22.
View which stocks have been most impacted by Coronavirus.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albemarle in the last year. There are currently 5 sell ratings, 13 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Albemarle.

Albemarle is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Albemarle.

Albemarle Co. (NYSE:ALB) issued its quarterly earnings results on Wednesday, August, 5th. The specialty chemicals company reported $0.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.72 by $0.14. Albemarle had a return on equity of 13.33% and a net margin of 12.99%.
View Albemarle's earnings history.

Albemarle announced a quarterly dividend on Tuesday, July 14th. Stockholders of record on Friday, September 18th will be paid a dividend of $0.385 per share on Thursday, October 1st. This represents a $1.54 annualized dividend and a dividend yield of 1.77%. The ex-dividend date is Thursday, September 17th.
View Albemarle's dividend history.

Albemarle updated its third quarter 2020 After-Hours earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $700-775 million, compared to the consensus revenue estimate of $717.55 million.

26 brokerages have issued 12-month price targets for Albemarle's stock. Their forecasts range from $39.50 to $116.00. On average, they expect Albemarle's share price to reach $77.73 in the next twelve months. This suggests that the stock has a possible downside of 10.9%.
View analysts' price targets for Albemarle.

Media stories about ALB stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Albemarle earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned media coverage about the specialty chemicals company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Albemarle.

Some companies that are related to Albemarle include Sherwin-Williams (SHW), Ecolab (ECL), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), Ashland Global (ASH), NewMarket (NEU), Quaker Chemical (KWR), Balchem (BCPC), W. R. Grace & Co (GRA), Stepan (SCL), HB Fuller (FUL), PolyOne (POL), Sensient Technologies (SXT) and Innospec (IOSP).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albemarle investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET), Wheaton Precious Metals (WPM), NVIDIA (NVDA), Rogers Communications (RCI) and Alibaba Group (BABA).

Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

Albemarle's stock is owned by a variety of institutional and retail investors. Top institutional investors include ProShare Advisors LLC (1.23%), KAMES CAPITAL plc (1.00%), US Bancorp DE (0.88%), Avalon Investment & Advisory (0.54%), New York State Common Retirement Fund (0.47%) and Marathon Asset Management LLP (0.47%). Company insiders that own Albemarle stock include Deeanne J Marlow, Eric Norris, Karen G Narwold, Luther C Iv Kissam and Scott Tozier.
View institutional ownership trends for Albemarle.

ALB stock was sold by a variety of institutional investors in the last quarter, including Eastern Bank, Robecosam AG, Edmond DE Rothschild Holding S.A., Zurcher Kantonalbank Zurich Cantonalbank, Capital Management Corp VA, Victory Capital Management Inc., Oregon Public Employees Retirement Fund, and Candriam Luxembourg S.C.A.. Company insiders that have sold Albemarle company stock in the last year include Karen G Narwold, Luther C Iv Kissam, and Scott Tozier.
View insider buying and selling activity for Albemarle.

ALB stock was bought by a variety of institutional investors in the last quarter, including Avalon Investment & Advisory, US Bancorp DE, Marathon Asset Management LLP, Zweig DiMenna Associates LLC, Hardman Johnston Global Advisors LLC, Great Lakes Advisors LLC, Moody Lynn & Lieberson LLC, and KAMES CAPITAL plc. Company insiders that have bought Albemarle stock in the last two years include Deeanne J Marlow, and Eric Norris.
View insider buying and selling activity for Albemarle.

Shares of ALB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALB stock can currently be purchased for approximately $87.22.

Albemarle has a market capitalization of $9.28 billion and generates $3.59 billion in revenue each year. The specialty chemicals company earns $533.23 million in net income (profit) each year or $6.04 on an earnings per share basis. Albemarle employs 6,000 workers across the globe.

The official website for Albemarle is www.albemarle.com.

Albemarle's mailing address is 4250 CONGRESS STREET SUITE 900, CHARLOTTE NC, 28209. The specialty chemicals company can be reached via phone at 980-299-5700 or via email at [email protected]